BACKGROUND INFORMATION ON THE PROCEDURE 
1. 
Submission of the dossier 
The applicant Bristol-Myers Squibb Pharma EEIG submitted on 2 December 2005 an application for 
Marketing  Authorisation  to  the  European  Medicines  Agency  (EMEA)  for  ORENCIA,  through  the 
centralised  procedure  falling  within  the  Article  3(1)  and  point  1  of  Annex  of  Regulation  (EC)  No 
726/2004. 
The legal basis for this application refers to:  
Article 8.3 of Directive 2001/83/EC, as amended - complete and independent application 
Scientific Advice: 
The applicant did not seek scientific advice at the CHMP. 
Licensing status: 
A new application was filed in the following countries: USA and Canada. 
The product was not licensed in any country at the time of submission of the application. 
The Rapporteur and Co-Rapporteur appointed by the CHMP were: 
Rapporteur: Pekka Kurki 
Co-Rapporteur: János Borvendég 
2. 
Steps taken for the assessment of the product 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
• 
The application was received by the EMEA on 2 December 2005. 
The procedure started on 28 December 2005.  
The  Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  8  March 
2006.  The  Co-Rapporteur's  first  Assessment  Report  was  circulated  to  all  CHMP  members  on  
7 March 2006.  
The quality list of questions was discussed and adopted at the Biological Working Party (BWP) 
meeting of 19-20 April 2006. 
During  the  meeting  on  24-27  April  2006,  the  CHMP  agreed  on  the  consolidated  List  of 
Questions to be sent to the applicant. The final consolidated List of Questions was sent to the 
applicant on 27 April 2006. 
The  applicant  submitted  the  responses  to  the  CHMP  consolidated  List  of  Questions  on  
4 October 2006. 
The Rapporteurs circulated the Joint Assessment Report on the applicant’s responses to the List 
of Questions to all CHMP members on 13 November 2006. 
The  quality  list  of  outstanding  issues  was  discussed  and  adopted  at  the  Biological  Working 
Party (BWP) meeting of 4-6 December 2006. 
During the CHMP meeting on 13-14 December 2006, the CHMP agreed on a list of outstanding 
issues to be addressed in writing and in an oral explanation by the applicant. 
The applicant submitted the responses to the CHMP consolidated List of Outstanding Issues on 
25 January 2007. 
During  the  BWP  meeting  on  12-14  February  2007,  outstanding  issues  were  addressed  by  the 
applicant during an oral explanation before the BWP and a recommendation to the CHMP was 
adopted. 
During the CHMP meeting on 19-22 February 2007, outstanding issues were addressed by the 
applicant during an oral explanation before the CHMP. 
The  Rapporteurs  circulated  the  Final  Joint  Assessment  Report  on  the  applicant’s  responses  to 
the remaining items of the List of Outstanding issues to all CHMP members on 08 March 2007. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
• 
• 
During the meeting on 19-22 March 2007, the CHMP, in the light of the overall data submitted 
and  the  scientific  discussion  within  the  Committee,  issued  a  positive  opinion  for  granting  a 
Marketing Authorisation to ORENCIA on 22 March 2007. The applicant provided the letter of 
undertaking on the follow-up measures to be fulfilled post-authorisation on 19 March 2007. 
The  CHMP  opinions  were  forwarded,  in  all  official  languages  of  the  European  Union,  to  the 
European Commission, which adopted the corresponding Decisions on 21 May 2007. 
 
 
